Transient receptor potential melastatin 6 and transient receptor potential melastatin 6/7 antagonists suppress colon adenocarcinoma HT-29 cells

Figure 3 Effects of transient receptor potential melastatin inhibitors on the viability of spheroid-derived cells. A: Cell viability of parental and spheroid (SP)-derived HT-29 cells treated with the Mg²⁺ channel inhibitor Co(III)hexamine; B: Cell viability of parental and SP cells treated with the transient receptor potential melastatin 6/7 inhibitor 2-aminoethyl diphenylborinate; C: Cell viability of parental and SP cells treated with the transient receptor potential melastatin 6 inhibitor Mesendogen; D: Cell viability of SP cells with or without Co(III)hexamine, 2-aminoethyl diphenylborinate, or Mesendogen treatment for 12 hours. SP: Spheroid; Co(III)hex: Co(III)hexamine; 2-APB: 2-aminoethyl diphenylborinate; ME: Mesendogen. ^aP < 0.05, ^bP < 0.01 vs the control spheroid group (n = 6).